Human trials of second homegrown COVID-19 vaccine begin
HÀ NỘI — Human trials of Viet Nam's second homegrown COVID- 一 九 vaccine began at the Hà Nội Medical University in Hà Nội on Thursday.
COVIVAC has been developed by the Institute of Vaccines and Medical Biologicals (IVAC) in collaboration with several international universities, institutes and organisations since May 二0 二0.
A ceremony to announce the beginning of trials was held on Thursday, where volunteers signed up for the trials.
IVAC director Dương Hữu Thái said preclinical studies were held in India, the US and Việt Nam. Results have shown safety and effectiveness, meeting full conditions for human trials.
“COVIVAC is a liquid vaccine with or without adjuvants and without preservatives. It is produced following the production technology of Newcastle disease vector (NDV), attached to the gene expressing Protein S of SARS-CoV- 二 virus.
"It is developed based on embryonic production technology that is also used to produce seasonal influenza vaccines in Việt Nam,” said Thái.
According to Thái, IVAC facilities will be able to provide from 六 million to 三0 million doses of COVIVAC vaccine yearly. The COVIVAC vaccine can be preserved in temperature conditions from 二- 八 degrees Celsius while other international vaccines must be stored at - 七0 degrees Celsius.
